Berwanger O, et al. - This study was designed in order to inspect if periprocedural loading doses of atorvastatin decreased 30-day major adverse cardiovascular events (MACE) in subjects with the acute coronary syndrome (ACS) and planned invasive management. No reduction was noted in the rate of MACE at 30 days through periprocedural loading doses of atorvastatin among patients with ACS and planned invasive management with percutaneous coronary intervention (PCI). Hence, the routine use of loading doses of atorvastatin was not supported among unselected patients with ACS and intended invasive management.